MX357446B - Agente terapeutico para dislipidemia. - Google Patents

Agente terapeutico para dislipidemia.

Info

Publication number
MX357446B
MX357446B MX2015003705A MX2015003705A MX357446B MX 357446 B MX357446 B MX 357446B MX 2015003705 A MX2015003705 A MX 2015003705A MX 2015003705 A MX2015003705 A MX 2015003705A MX 357446 B MX357446 B MX 357446B
Authority
MX
Mexico
Prior art keywords
dyslipidemia
prevention
treatment
therapeutic agent
formula
Prior art date
Application number
MX2015003705A
Other languages
English (en)
Other versions
MX2015003705A (es
Inventor
Takizawa Toshiaki
Yoshinaka Yasunobu
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of MX2015003705A publication Critical patent/MX2015003705A/es
Publication of MX357446B publication Critical patent/MX357446B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención aborda el problema de la provisión de una composición de combinación farmacéutica y combinaciones de fármacos para la prevención y/o tratamiento de condiciones dislipidémicas tales como aterosclerosis, hipercolesterolemia, enfermedad de HDL baja en la sangre, en mamíferos incluso los humanos. Una composición farmacéutica para la prevención y/o tratamiento de dislipidemia, etc., que comprende (a) un compuesto representado por la fórmula general (1) (en la fórmula, cada símbolo es el mismo definido en la especificación) o una sal del mismo o un solvato del mismo, y (b) un inhibidor de la absorción de colesterol.
MX2015003705A 2012-09-27 2013-09-27 Agente terapeutico para dislipidemia. MX357446B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012214635 2012-09-27
PCT/JP2013/005756 WO2014050134A1 (ja) 2012-09-27 2013-09-27 脂質異常症治療剤

Publications (2)

Publication Number Publication Date
MX2015003705A MX2015003705A (es) 2015-06-10
MX357446B true MX357446B (es) 2018-07-10

Family

ID=50387566

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003705A MX357446B (es) 2012-09-27 2013-09-27 Agente terapeutico para dislipidemia.

Country Status (21)

Country Link
US (4) US9572798B2 (es)
EP (1) EP2902025B1 (es)
JP (1) JP6238460B2 (es)
KR (1) KR102098032B1 (es)
CN (1) CN104640544B (es)
AU (1) AU2013321918B2 (es)
BR (1) BR112015006305B1 (es)
CA (1) CA2901650C (es)
EA (1) EA024873B1 (es)
ES (1) ES2752039T3 (es)
HK (1) HK1206620A1 (es)
IL (1) IL237981B (es)
IN (1) IN2015DN02966A (es)
MX (1) MX357446B (es)
MY (1) MY177686A (es)
PH (1) PH12015500471B1 (es)
PL (1) PL2902025T3 (es)
PT (1) PT2902025T (es)
SG (1) SG11201501740XA (es)
TW (1) TWI598098B (es)
WO (1) WO2014050134A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI691331B (zh) * 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
KR102512518B1 (ko) * 2017-06-30 2023-03-21 교와 가부시키가이샤 페마피브레이트를 함유하는 의약
JP7425603B2 (ja) * 2017-06-30 2024-01-31 興和株式会社 医薬組成物
EP3646867A4 (en) * 2017-06-30 2021-03-24 Kowa Company, Ltd. PHARMACEUTICAL COMPOSITION
CN110809469A (zh) * 2017-06-30 2020-02-18 兴和株式会社 医药组合物
US20200121648A1 (en) * 2017-06-30 2020-04-23 Kowa Company, Ltd. Pharmaceutical composition
US11298340B2 (en) 2017-06-30 2022-04-12 Kowa Company, Ltd. Pharmaceutical composition
CN110809470A (zh) * 2017-06-30 2020-02-18 兴和株式会社 医药品
WO2019004447A1 (ja) * 2017-06-30 2019-01-03 興和株式会社 医薬組成物
US11446282B2 (en) 2017-12-21 2022-09-20 Kowa Company, Ltd. Methods of treating mixed dyslipidemia and hypertriglycertdemia
JP2021506907A (ja) * 2017-12-21 2021-02-22 興和株式会社 高トリグリセライド血症の治療方法
EP3903782A4 (en) * 2018-12-27 2022-10-05 Kowa Company, Ltd. PHARMACEUTICAL COMPOSITION

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51449B (sr) 2001-01-26 2011-04-30 Schering Corporation Kombinacija aktivatora peroksizom proliferator-aktiviranog receptora (ppar) i inhibitora apsorpcije sterola i lečenje vaskularnih indikacija
US7205321B2 (en) 2001-11-15 2007-04-17 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
WO2005009942A1 (ja) 2003-07-28 2005-02-03 Kyorin Pharmaceutical Co., Ltd. 光学活性置換フェニルプロピオン酸誘導体
CN100425594C (zh) * 2003-09-03 2008-10-15 兴和株式会社 Ppar活性化化合物及含该化合物的医药组合物
MXPA06002435A (es) 2003-09-03 2006-06-20 Kowa Co Compuesto activador del receptor activado por el proliferador de peroxisoma y composicion farmaceutica que lo contiene.
DE102004016845A1 (de) 2004-04-07 2005-10-27 Bayer Healthcare Ag Phenylthioessigsäure-Derivate und ihre Verwendung
WO2006033891A2 (en) 2004-09-16 2006-03-30 Merck & Co., Inc. Compounds for the treatment of dyslipidemia and other lipid disorders
TWI359810B (en) 2004-11-04 2012-03-11 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivative containing thiazole rin
WO2007008529A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc Celullar cholesterol absorption modifiers
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
WO2008033464A2 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives for the treatment of disorders of the lipid metabolism
WO2008104875A1 (en) 2007-03-01 2008-09-04 Pfizer Products Inc. Oxazolidinones as cholesterol absorption inhibitors
TWI407955B (zh) 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及/或治療劑
WO2009047240A1 (en) 2007-10-09 2009-04-16 Smithkline Beecham Corporation Indole derivatives useful as ppar activators
DE102007061757A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung

Also Published As

Publication number Publication date
PH12015500471A1 (en) 2015-04-20
BR112015006305A2 (pt) 2017-07-04
BR112015006305B1 (pt) 2020-11-17
CN104640544A (zh) 2015-05-20
US20180185337A1 (en) 2018-07-05
TWI598098B (zh) 2017-09-11
CA2901650C (en) 2021-05-04
IL237981A0 (en) 2015-05-31
US9572798B2 (en) 2017-02-21
US20190167645A1 (en) 2019-06-06
WO2014050134A1 (ja) 2014-04-03
US9931321B2 (en) 2018-04-03
EA201590653A1 (ru) 2015-07-30
KR20150063035A (ko) 2015-06-08
CA2901650A1 (en) 2014-04-03
US20150196538A1 (en) 2015-07-16
CN104640544B (zh) 2017-05-03
KR102098032B1 (ko) 2020-04-07
EP2902025A1 (en) 2015-08-05
IN2015DN02966A (es) 2015-09-18
TW201417811A (zh) 2014-05-16
PT2902025T (pt) 2019-11-04
US20170112811A1 (en) 2017-04-27
PH12015500471B1 (en) 2015-04-20
US11013722B2 (en) 2021-05-25
IL237981B (en) 2020-05-31
SG11201501740XA (en) 2015-04-29
PL2902025T3 (pl) 2020-03-31
EP2902025B1 (en) 2019-08-07
AU2013321918A1 (en) 2015-04-23
MY177686A (en) 2020-09-23
HK1206620A1 (en) 2016-01-15
US10258609B2 (en) 2019-04-16
EA024873B1 (ru) 2016-10-31
ES2752039T3 (es) 2020-04-02
JPWO2014050134A1 (ja) 2016-08-22
JP6238460B2 (ja) 2017-11-29
EP2902025A4 (en) 2016-03-02
AU2013321918B2 (en) 2018-05-10
MX2015003705A (es) 2015-06-10

Similar Documents

Publication Publication Date Title
PH12015500471A1 (en) Therapeutic agent for dyslipidemia
PH12017501306A1 (en) Inhibitors of histone demethylases
PH12016502582A1 (en) TrK-INHIBITING COMPOUND
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
EA201690283A1 (ru) Композиции и терапевтические способы для ускоренного регресса бляшки
BR112015005117A2 (pt) métodos de tratamento da doença de alzheimer e suas composições farmacêuticas
BR112015022674A2 (pt) inibidores de bromodomínio
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112014021531A8 (pt) composto, composição farmacêutica e usos dos mesmos
BR112014009415A2 (pt) inibidores de arginase e suas aplicações terapêuticas
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
EA201200098A1 (ru) Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия
WO2013040227A3 (en) Therapeutic compounds
CN107406464A8 (zh) 精氨酸酶抑制剂及其治疗用途
IN2014DN06869A (es)
MX2015014083A (es) Inhibidores de enzima de escision de proteina precursora beta-amiloide (app) en el sitio beta 1 (bace1).
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
EA201690284A1 (ru) Композиции и терапевтические способы для ускоренного регресса бляшки
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
EA201591175A1 (ru) Трициклические соединения в качестве ингибиторов cftr
CL2014003607A1 (es) Compuestos derivados de benzodioxol, inhibidores de la acetilcolinesterasa; metodo de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o el tratamiento de la enfermedad de alzheimer.
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA201600411A1 (ru) Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний
EA201390619A1 (ru) 3-замещенные 6-(пиридинилметокси)пирролопиридиновые соединения

Legal Events

Date Code Title Description
FG Grant or registration